Related Experiment Videos
Profiling risk from arrhythmic or hemodynamic death
E de Teresa1, J Alzueta, M Jiménez-Navarro
1Department of Cardiology, Hospital Clínico Virgen de la Victoria, Universidad de Málaga, Málaga, Spain.
Insights
Sudden cardiac death (SCD) is a major cause of mortality in congestive heart failure patients. Identifying candidates for therapies like implantable cardioverter defibrillators is crucial for reducing SCD.
Area of Science:
- Cardiology
- Heart Failure Research
Background:
- Congestive heart failure (CHF) prevalence is rising, with high mortality despite therapeutic advances.
- Sudden cardiac death (SCD) accounts for nearly half of all deaths in CHF patients.
- SCD's contribution to mortality varies with heart failure severity.
Purpose of the Study:
- To review the mechanisms and impact of SCD in congestive heart failure.
- To discuss current and potential therapeutic strategies for preventing SCD in CHF.
Main Methods:
- Literature review of studies on congestive heart failure and sudden cardiac death.
- Analysis of mortality data and mechanisms of SCD in different stages of heart failure.
- Evaluation of the role of implantable cardioverter defibrillators (ICDs) in preventing arrhythmic death.
Main Results:
- SCD is a significant cause of mortality in CHF, particularly in early stages.
- Mechanisms of SCD include ventricular arrhythmias, bradyarrhythmias, and other cardiovascular events.
- Ventricular tachycardia (VT) or ventricular fibrillation (VF) cause SCD in a minority of advanced CHF patients.
Conclusions:
- Effective therapies, such as ICDs, can reduce SCD burden in CHF.
- Accurate identification of high-risk patients is essential for successful SCD prevention strategies.
- Further research is needed to optimize patient selection for prophylactic therapies.
Abstract:
Congestive heart failure is increasing in prevalence and, despite recent advances in therapy, mortality remains high. Sudden cardiac death (SCD) represents a significant percentage of overall mortality, accounting for almost 1 in 2 deaths in patients with congestive heart failure. In patients with asymptomatic left ventricular dysfunction or mild degrees of functional impairement, overall annual mortality is low, although a significant portion of the deaths are sudden; on the other hand, in advanced heart failure annual mortality increases, but SCD contributes to it to a lesser degree. The mechanisms of SCD in heart failure are multiple, including ventricular tachycardia/ventricular fibrillation, bradyarrhythmias, electromechanical dissociation, acute coronary events, and thromboembolic events. Only a minority of patients with advanced heart failure or on the waiting list for heart transplant experience SCD as a consequence of ventricular tachycardia (VT) or ventricular fibrillation (VF). The availability of effective therapies to prevent sudden arrhythmic death, such as that provided by automatic implantable cardioverter defibrillators, may help to reduce the burden of SCD in congestive heart failure, but major efforts will be needed to identify the candidates who may benefit from this approach.